Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma

N. Babae, M. Bourajjaj, Y. Liu, J.R. Beijnum, F. Cerisoli, P.V. Scaria, Mark Verheul, M.P. Berkel, E.H. Pieters, R.J. van Haastert, A. Yousefi, E. Mastrobattista, Gerrit Storm, E. Berezikov, E. Cuppen, M. Woodle, R.Q.J. Schaapveld, G.P. Prevost, A.W. Griffioen, P.I. NoortR.M. Schiffelers

Research output: Contribution to journalArticleAcademicpeer-review

64 Citations (Scopus)
80 Downloads (Pure)

Abstract

Tumor-angiogenesis is the multi-factorial process of sprouting of endothelial cells (EC) into micro-vessels to provide tumor cells with nutrients and oxygen. To explore miRNAs as therapeutic angiogenesis-inhibitors, we performed a functional screen to identify miRNAs that are able to decrease EC viability. We identified miRNA-7 (miR-7) as a potent negative regulator of angiogenesis. Introduction of miR-7 in EC resulted in strongly reduced cell viability, tube formation, sprouting and migration. Application of miR-7 in the chick chorioallantoic membrane assay led to a profound reduction of vascularization, similar to anti-angiogenic drug sunitinib. Local administration of miR-7 in an in vivo murine neuroblastoma tumor model significantly inhibited angiogenesis and tumor growth. Finally, systemic administration of miR-7 using a novel integrin-targeted biodegradable polymeric nanoparticles that targets both EC and tumor cells, strongly reduced angiogenesis and tumor proliferation in mice with human glioblastoma xenografts. Transcriptome analysis of miR-7 transfected EC in combination with in silico target prediction resulted in the identification of OGT as novel target gene of miR-7. Our study provides a comprehensive validation of miR-7 as novel anti-angiogenic therapeutic miRNA that can be systemically delivered to both EC and tumor cells and offers promise for miR-7 as novel anti-tumor therapeutic.
Original languageUndefined
Pages (from-to)6687-6700
JournalOncotarget
Volume5
Issue number16
DOIs
Publication statusPublished - 2014

Keywords

  • IR-95146
  • METIS-309475

Cite this

Babae, N., Bourajjaj, M., Liu, Y., Beijnum, J. R., Cerisoli, F., Scaria, P. V., ... Schiffelers, R. M. (2014). Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. Oncotarget, 5(16), 6687-6700. https://doi.org/10.18632/oncotarget.2235
Babae, N. ; Bourajjaj, M. ; Liu, Y. ; Beijnum, J.R. ; Cerisoli, F. ; Scaria, P.V. ; Verheul, Mark ; Berkel, M.P. ; Pieters, E.H. ; van Haastert, R.J. ; Yousefi, A. ; Mastrobattista, E. ; Storm, Gerrit ; Berezikov, E. ; Cuppen, E. ; Woodle, M. ; Schaapveld, R.Q.J. ; Prevost, G.P. ; Griffioen, A.W. ; Noort, P.I. ; Schiffelers, R.M. / Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. In: Oncotarget. 2014 ; Vol. 5, No. 16. pp. 6687-6700.
@article{320a6c6c45c3445ab1b50d918d0ad32d,
title = "Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma",
abstract = "Tumor-angiogenesis is the multi-factorial process of sprouting of endothelial cells (EC) into micro-vessels to provide tumor cells with nutrients and oxygen. To explore miRNAs as therapeutic angiogenesis-inhibitors, we performed a functional screen to identify miRNAs that are able to decrease EC viability. We identified miRNA-7 (miR-7) as a potent negative regulator of angiogenesis. Introduction of miR-7 in EC resulted in strongly reduced cell viability, tube formation, sprouting and migration. Application of miR-7 in the chick chorioallantoic membrane assay led to a profound reduction of vascularization, similar to anti-angiogenic drug sunitinib. Local administration of miR-7 in an in vivo murine neuroblastoma tumor model significantly inhibited angiogenesis and tumor growth. Finally, systemic administration of miR-7 using a novel integrin-targeted biodegradable polymeric nanoparticles that targets both EC and tumor cells, strongly reduced angiogenesis and tumor proliferation in mice with human glioblastoma xenografts. Transcriptome analysis of miR-7 transfected EC in combination with in silico target prediction resulted in the identification of OGT as novel target gene of miR-7. Our study provides a comprehensive validation of miR-7 as novel anti-angiogenic therapeutic miRNA that can be systemically delivered to both EC and tumor cells and offers promise for miR-7 as novel anti-tumor therapeutic.",
keywords = "IR-95146, METIS-309475",
author = "N. Babae and M. Bourajjaj and Y. Liu and J.R. Beijnum and F. Cerisoli and P.V. Scaria and Mark Verheul and M.P. Berkel and E.H. Pieters and {van Haastert}, R.J. and A. Yousefi and E. Mastrobattista and Gerrit Storm and E. Berezikov and E. Cuppen and M. Woodle and R.Q.J. Schaapveld and G.P. Prevost and A.W. Griffioen and P.I. Noort and R.M. Schiffelers",
year = "2014",
doi = "10.18632/oncotarget.2235",
language = "Undefined",
volume = "5",
pages = "6687--6700",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "16",

}

Babae, N, Bourajjaj, M, Liu, Y, Beijnum, JR, Cerisoli, F, Scaria, PV, Verheul, M, Berkel, MP, Pieters, EH, van Haastert, RJ, Yousefi, A, Mastrobattista, E, Storm, G, Berezikov, E, Cuppen, E, Woodle, M, Schaapveld, RQJ, Prevost, GP, Griffioen, AW, Noort, PI & Schiffelers, RM 2014, 'Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma', Oncotarget, vol. 5, no. 16, pp. 6687-6700. https://doi.org/10.18632/oncotarget.2235

Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. / Babae, N.; Bourajjaj, M.; Liu, Y.; Beijnum, J.R.; Cerisoli, F.; Scaria, P.V.; Verheul, Mark; Berkel, M.P.; Pieters, E.H.; van Haastert, R.J.; Yousefi, A.; Mastrobattista, E.; Storm, Gerrit; Berezikov, E.; Cuppen, E.; Woodle, M.; Schaapveld, R.Q.J.; Prevost, G.P.; Griffioen, A.W.; Noort, P.I.; Schiffelers, R.M.

In: Oncotarget, Vol. 5, No. 16, 2014, p. 6687-6700.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma

AU - Babae, N.

AU - Bourajjaj, M.

AU - Liu, Y.

AU - Beijnum, J.R.

AU - Cerisoli, F.

AU - Scaria, P.V.

AU - Verheul, Mark

AU - Berkel, M.P.

AU - Pieters, E.H.

AU - van Haastert, R.J.

AU - Yousefi, A.

AU - Mastrobattista, E.

AU - Storm, Gerrit

AU - Berezikov, E.

AU - Cuppen, E.

AU - Woodle, M.

AU - Schaapveld, R.Q.J.

AU - Prevost, G.P.

AU - Griffioen, A.W.

AU - Noort, P.I.

AU - Schiffelers, R.M.

PY - 2014

Y1 - 2014

N2 - Tumor-angiogenesis is the multi-factorial process of sprouting of endothelial cells (EC) into micro-vessels to provide tumor cells with nutrients and oxygen. To explore miRNAs as therapeutic angiogenesis-inhibitors, we performed a functional screen to identify miRNAs that are able to decrease EC viability. We identified miRNA-7 (miR-7) as a potent negative regulator of angiogenesis. Introduction of miR-7 in EC resulted in strongly reduced cell viability, tube formation, sprouting and migration. Application of miR-7 in the chick chorioallantoic membrane assay led to a profound reduction of vascularization, similar to anti-angiogenic drug sunitinib. Local administration of miR-7 in an in vivo murine neuroblastoma tumor model significantly inhibited angiogenesis and tumor growth. Finally, systemic administration of miR-7 using a novel integrin-targeted biodegradable polymeric nanoparticles that targets both EC and tumor cells, strongly reduced angiogenesis and tumor proliferation in mice with human glioblastoma xenografts. Transcriptome analysis of miR-7 transfected EC in combination with in silico target prediction resulted in the identification of OGT as novel target gene of miR-7. Our study provides a comprehensive validation of miR-7 as novel anti-angiogenic therapeutic miRNA that can be systemically delivered to both EC and tumor cells and offers promise for miR-7 as novel anti-tumor therapeutic.

AB - Tumor-angiogenesis is the multi-factorial process of sprouting of endothelial cells (EC) into micro-vessels to provide tumor cells with nutrients and oxygen. To explore miRNAs as therapeutic angiogenesis-inhibitors, we performed a functional screen to identify miRNAs that are able to decrease EC viability. We identified miRNA-7 (miR-7) as a potent negative regulator of angiogenesis. Introduction of miR-7 in EC resulted in strongly reduced cell viability, tube formation, sprouting and migration. Application of miR-7 in the chick chorioallantoic membrane assay led to a profound reduction of vascularization, similar to anti-angiogenic drug sunitinib. Local administration of miR-7 in an in vivo murine neuroblastoma tumor model significantly inhibited angiogenesis and tumor growth. Finally, systemic administration of miR-7 using a novel integrin-targeted biodegradable polymeric nanoparticles that targets both EC and tumor cells, strongly reduced angiogenesis and tumor proliferation in mice with human glioblastoma xenografts. Transcriptome analysis of miR-7 transfected EC in combination with in silico target prediction resulted in the identification of OGT as novel target gene of miR-7. Our study provides a comprehensive validation of miR-7 as novel anti-angiogenic therapeutic miRNA that can be systemically delivered to both EC and tumor cells and offers promise for miR-7 as novel anti-tumor therapeutic.

KW - IR-95146

KW - METIS-309475

U2 - 10.18632/oncotarget.2235

DO - 10.18632/oncotarget.2235

M3 - Article

VL - 5

SP - 6687

EP - 6700

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -